SOLICITATION NOTICE
B -- Workplace Exposure, Inflammation and Cardiovascular Toxicity
- Notice Date
- 5/30/2014
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Acquisition and Assistance Field Branch (Morgantown), 1095 Willowdale Road, Morgantown, West Virginia, 26505
- ZIP Code
- 26505
- Solicitation Number
- 000HCCCC-2014-72542
- Archive Date
- 7/13/2014
- Point of Contact
- Rebecca S Mullenax, Phone: 304-285-5880, Denise Rains, Phone: 509-354-8111
- E-Mail Address
-
rmullenax@cdc.gov, dgr8@cdc.gov
(rmullenax@cdc.gov, dgr8@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Title: Workplace Exposure, Inflammation, & Cardiovascular Toxicity - Seromic Meditors of Carbon Nanotube Induced Systemic Bioactivation. The Centers for Disease Control and Prevention (CDC) and the National Institute for Occupational Safety and Health (NIOSH), Pathology and Physiology Research Branch (PPRB), Health Effects Laboratory Division (HELD) intends to award a sole source firm fixed price purchase order to Virginia Commonwealth University, 912 W, Franklin Street, Richard, VA 23284-9040 for a two year circulating factors study. Clin 1: Quantity of one (1) - Two year study to determine circulating factors after Multi-Walled Carbon Nanotubes (MWCNT) pulmonary exposure. STATEMENT OF WORK Title of Project: Workplace Exposure, Inflammation, & Cardiovascular Toxicity - Seromic Meditors of Carbon Nanotube I nduced Systemic Bioactivation Background and Need -Exposure to multi-walled carbon nanotubes (MWCNT) represents a novel risk to human health with its increased use i n manufacturing. Recent animal studies offer evidence that MWCNT i nhalation may induce pulmonary i nflammation and systemic effects in the vasculature and other organ systems. However, MWCNT itself i s fou nd at minute q uantities outside of the lung, suggesting that the observed systemic bioactivati on is transduced by unid entified circulating factor(s). I n thi s project we hypothesize that the inflammat ory respon se to MWCNT with in the lung i nd uces the release of by-product factors into circulati on that convey bioactivity in the vasculature and bey ond. We propose use of unbiased quantitative methods to characterize the molecular constituents within the blood of anim als exposed to MWCNT at two different concent rations relative to control treatment. We further wi ll assess the transmissibilit y of the identified blood factors into the centra l nervou s system (CNS) via cerebrospinal fluid (CSF) anal ysis. These studies w ill com plement ongoing functi onal assessments both i n the vasculature and bra i n. Our expected findings will prov ide preli mi nary evidence for a novel mechani sm by which inhalation exposure transduces systemic health effects, with significant mechanistic implications for human health in the manufacturin g sector. Scope of Work Aim 1: Interrogate the "serome" response to MWCNT pha ryn geal aspi ration. Emp loy supervised statistical meth ods to discriminate robust molecul ar mea sures in blood serum as a response to I 0 µg and 40 µg aspirations of M WCNT in mice, termed here the "serome". Mea sures w ill support a nove l hypothe si s relatin g systemic bioactivation with the combinatorial bi ochemi stry presentation of m olecules into the blood followi ng exposure to xenobi otic agents in the air. Aim 2 : Ident i fy factors comprisi ng the MWCNT "serome" and its dose-dependent response. Generate selection l ist from resul ts of Ai m I to interrogate companion tandem mass spectrometric data for endogenous peptid e sequences. Avai lable sequence search methods wi ll be employed with variation of tolerance and input protein database variab les to provide a fi rst pass eva luation of the data. Separate ly, factors found to d ifferentiate the I 0 and 40 µg dose will be evaluated for identifiable peptide sequences to assess biochemica l differences between those factors that response to both l evels of MWCNT from those that are dose-select ive. While the number of identified sequences will be limited in thi s initial work, we expect that these sequences wi ll further our understanding of the i nterconnection between the pulm onary respon se to MWCNT and systemic vascular and neurol ogical effects. Aim 3: Assess the transm ission of seromic factors into the CNS. Through collaboration with NIOSH, we will obtain mat ched sets of bl ood and CSF samples from mice 4h after receivi ng MWCNT pharyngeal aspirations at a I0 µg occupationally relevant dose relativ e to dispersi on media treated mice (n=6 /grp.). Samples wi ll be proce ssed to denature and uncouple seromic factors within blood serum and CSF samples and interrogated by liquid chromatography I ion mobil ity spectroscopyI tandem mass spectrometry using a data-independent approach. Results wi ll be interrogated by supervised stati stical methods to resolve discriminant molecules present wi thi n the blood and CSF compartments of M WCNT dosed ani mals relative to mice recei ving d ispersion m edia only. Results are expected to prov ide i nitial proof-of-principle for the transmi ssion of seromic factors into the CNS whereby cell s are directly bioactivated. Report ing Schedule - The University all the necessary equipment to determine the circulating factors following a pulm onary exposure. Project progress will be tracked by the NIOSH project officer and payment will be released once a milestone is reached. This contract is broken down into three aims and payment will be disbursed following completion of each aim as follows: completion of Aim I -34%, Aim 2 - 33%, Aim 3 -33%. Successful completion of each Aim will be determined by the NIOSH Project Officer. The University's laboratory has performed similar analysis on samples collected from air pollution studies and there is no anticipationof issues with this project going forward. Deliverables -The NIOSH project officer will publish research findings in collaboration with the University. The University is fully aware of the requirements to publi sh with NIOSH and will allow for at least 30 days of clearance prior to submitting any published work. All publications will be evaluated an approved by the NIOSH project officer and cleared by N IOSH prior to submi ssion.his contract action is for a product for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 10 U.S.C 2304(c) (1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. The notice of intent is not a request for competitive quotations; however, all quotations/responses received within (15) days of the issuance of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be e-mailed to purchasing agent Rebecca Mullenax at rmullenax@cdc.gov by 11:59 p.m., Eastern Time on June 13, 2014. FAR Reference: FAR 5.207 - Preparation and transmittal of synopses under (c) (15), (c) (16) (i) and (c) (16) (ii).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/MNIOSH/000HCCCC-2014-72542/listing.html)
- Place of Performance
- Address: United States
- Record
- SN03381463-W 20140601/140531022103-28ff9e71e2f8a1d0f73e4a572a11fc1e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |